To make matters worse, the biotech realized that the same duff drug product had been used in a separate ongoing study of ...

After issues with a batch of Jasper Therapeutics' investigational antibody led to "lower" therapeutic effects in several ...

Jasper Therapeutics’ stock has dropped by more than 50% after the company announced it was looking into the impact of a ...

Jasper Therapeutics faced a wave of downgrades Monday after disclosing that a compromised drug product lot disrupted results ...

Shares of Jasper Therapeutics plummeted in premarket trading Monday after the clinical-stage biotechnology company said issues with one lot of its lead drug candidate briquilimab was disrupting ...

The study will be conducted at sites in the US and EU and Jasper is expecting to enroll the first patient by the end of 2023 and to be able to report data from early cohorts by mid-2024.

Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6th, 2025, including the recently added 180mg Q8W dose cohort.

Aptinyx Recommences Phase 2 Study of NYX-458 in Patients with Cognitive Impairment Associated with Parkinson’s Disease Dementia and Dementia with Lewy Bodies ...

NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic alternatives ...

Jasper Therapeutics reports promising SPOTLIGHT study results for briquilimab in treating chronic inducible urticaria with favorable safety outcomes.

(RTTNews) - Aptinyx Inc. (APTX) said that a phase 2b study of NYX-2925 in Fibromyalgia did not achieve statistically significant separation from placebo on the study's primary endpoint, which ...